A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis

NCT01042158 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Arterial Hypertension
Systemic Sclerosis
Scleroderma Spectrum of Diseases
Connective Tissue Disease
Pulmonary Hypertension

Interventions

DRUG: tadalafil and ambrisentan upfront combination therapy

Sponsor

Johns Hopkins University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]